Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...143144145146147148149150151152153...10651066»
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion:  HAIRCUSH: Hair Cortisol and Cushing's Disease (clinicaltrials.gov) -  Jul 20, 2023   
    P=N/A,  N=51, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jul 2023 Recruiting --> Completed
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Fabrication, Characterization and Biomedical Evaluation of a Statistically Optimized Gelatin Scaffold Enriched with Co-Drugs Loaded into Controlled-Release Silica Nanoparticles. (Pubmed Central) -  Jul 18, 2023   
    The current study focused on the fabrication of a well-designed, biocompatible, physically stable, non-irritating and highly porous gelatin scaffold loaded with controlled-release triamcinolone acetonide (TA) and econazole nitrate (EN) co-loaded into mesoporous silica nanoparticles (EN-TA-loaded MSNs) to provide a better long-lasting antifungal therapeutic effect with minimal unfavorable effects...Similarly, the MSNs-loaded scaffold showed a decreased cytotoxicity because the cell survival rate in the scaffold presence was 89% while the cell survival rate was 85% in the case of the pure drugs, and the MSNs-loaded scaffold did not indicate any grade of erythema on the skin in comparison to the pure medicinal agents. Conclusively, the scaffold-loaded nanoparticles containing the combined therapy appear to possess a strong prospective for enhancing patients' adherence and therapy tolerance by yielding improved synergistic antifungal efficacy at a low dose with abridged toxicity and augmented wound-healing impact.
  • ||||||||||  dexamethasone injection / Generic mfg., spironolactone / Generic mfg., Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Ambiguous Contribution of Glucocorticosteroids to Acute Neuroinflammation in the Hippocampus of Rat. (Pubmed Central) -  Jul 18, 2023   
    The modulation of GR and MR was performed by dexamethasone (GR activation), mifepristone, and spironolactone (GR and MR inhibition, respectively)...In contrast to GR activation, GR or MR inhibition had virtually no influence on LPS-induced inflammatory response. The results suggest glucocorticosteroids ambiguously modulate specific aspects of neuroinflammatory response in the hippocampus of rats at molecular and cellular levels.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Role of Chondroitin Sulfate Proteoglycan 5 in Steroid-Induced Cataract. (Pubmed Central) -  Jul 18, 2023   
    In this study, we verified the effect of chondroitin sulfate proteoglycan 5 (CSPG5) using dexamethasone (dexa)-treated human lens epithelial (HLE-B3) cells and the lens epithelium from the anterior capsule of SIC patients obtained during cataract surgery...Taken together, these results indicate that the steroid-induced effects on lens epithelial cells are mediated via alterations in CSPG5 expression. Therefore, our study emphasizes the potential of CSPG5 as a therapeutic target for the prevention and treatment of SIC.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  The influence of COVID-19 on colorectal cancer was investigated using bioinformatics and systems biology techniques. (Pubmed Central) -  Jul 17, 2023   
    The ten predicted drugs include troglitazone, estradiol, progesterone, calcitriol, genistein, dexamethasone, lucanthone, resveratrol, retinoic acid, phorbol 12-myristate 13-acetate, some of which have been investigated as potential CRC and COVID-19 therapies. By clarifying the relationship between COVID-19 and CRC, we hope to provide novel clues and promising therapeutic drugs to treat these two illnesses.
  • ||||||||||  Review, Journal, Machine learning:  Experimental drugs in clinical trials for COPD: Artificial Intelligence via Machine Learning approach to predict the successful advance from early-stage development to approval. (Pubmed Central) -  Jul 17, 2023   
    Different ML models, trained from prior knowledge on clinical trial success, were used to predict the probability that experimental drugs will successfully advance toward approval in COPD, according to Bayesian inference as follows: ?25% low probability, >25% and???50% moderate probability, >50% and???75% high probability, and?>?75% very high probability. The Artificial Neural Network and Random Forest ML models indicated that, among the current experimental drugs in clinical trials for COPD, only the bifunctional muscarinic antagonist - ?-adrenoceptor agonists (MABA) navafenterol and batefenterol, the inhaled corticosteroid (ICS)/MABA fluticasone furoate/batefenterol, and the bifunctional phosphodiesterase (PDE) 3/4 inhibitor ensifentrine resulted to have a moderate to very high probability of being approved in the next future, however not before 2025.
  • ||||||||||  QVAR (beclomethasone dipropionate hydrofluoroalkane inhalation) / Teva
    Journal:  Scrutinizing interlinkages between digitalization, economic complexity, green technologies, green energy consumption and CO emission by quantile spillovers in Vietnam. (Pubmed Central) -  Jul 17, 2023   
    We use quantile vector autoregression (QVAR) to identify the connection between six variables related to digitalization (proxied by a number of Internet users and mobile cellular subscriptions), green technology development, green energy consumption, carbon dioxide emissions, and economic complexity index from 1996 to 2019 in Vietnam...In the short term, there was volatility, especially from 2009 to 2013, due to unprecedented events like destructive changes in political, economic, and financial issues in the globe. Our findings are critical for economists and policymakers in promoting a country's digitalization, green technology performance, and green energy on the path toward sustainable development.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion date:  MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty (clinicaltrials.gov) -  Jul 17, 2023   
    P=N/A,  N=130, Active, not recruiting, 
    Trial completion date: Mar 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Feb 2024 Trial completion date: May 2023 --> Dec 2024
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Hydrocortisone in severe community-acquired pneumonia. (Pubmed Central) -  Jul 16, 2023   
    Compared with placebo, the combination of intravenous and topical dexamethasone can reduce pain, swelling, and inflammation after TKA, it also can improve functional recovery and reduce the incidence of postoperative nausea and vomiting. No abstract available
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Cushing Syndrome: A Review. (Pubmed Central) -  Jul 15, 2023   
    Screening for elevated cortisol is performed with a 24-hour urinary free cortisol test or late-night salivary cortisol test or by evaluating whether cortisol is suppressed the morning after an evening dexamethasone dose...First-line therapy for Cushing syndrome due to endogenous overproduction of cortisol is surgery to remove the causative tumor. Many patients will require additional treatment with medications, radiation, or bilateral adrenalectomy.
  • ||||||||||  cyclophosphamide / Generic mfg., budesonide / Generic mfg.
    Therapeutic Dilemmas in Glomerular Diseases (Room 204, Pennsylvania Convention Center) -  Jul 15, 2023 - Abstract #KIDNEYWEEK2023KIDNEY_WEEK_43;    
    This session covers selected topics in the treatment of glomerular diseases in which there is a level of uncertainty regarding appropriate therapy. Learning Objective(s) Summarize the use of corticosteroids in IgA nephropathy, including delayed release formulation of budesonide Describe appropriate use of combination cyclophosphamide and corticosteroids in primary membranous nephropathy Discuss appropriate therapy for steroid-resistant primary FSGS Explain the role of adding SGLT2 inhibitors in the treatment of primary glomerular diseases
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Corticosteroid-Associated Avascular Necrosis of the Femoral Head in Patients with Severe COVID-19: A Single-Center Study. (Pubmed Central) -  Jul 15, 2023   
    Learning Objective(s) Summarize the use of corticosteroids in IgA nephropathy, including delayed release formulation of budesonide Describe appropriate use of combination cyclophosphamide and corticosteroids in primary membranous nephropathy Discuss appropriate therapy for steroid-resistant primary FSGS Explain the role of adding SGLT2 inhibitors in the treatment of primary glomerular diseases Moderate cases received 2
  • ||||||||||  simvastatin / Generic mfg.
    Journal, Immunomodulating:  Can Simvastatin Reduce the Need for Immunomodulatory Drugs to Treat Uveitis?: A (Pubmed Central) -  Jul 15, 2023   
    The results suggest that it may extend the time to disease relapse among those who achieve disease quiescence. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Clinical, Retrospective data, Review, Journal:  How do we (Pubmed Central) -  Jul 14, 2023   
    This study demonstrates that the combination of G-CSF and dexamethasone donor stimulation, followed by apheresis granulocyte collection, is safe and can reliably yield a high-dose product. Consistent production of high-dose units allows for better assessment of patient outcomes by reducing dosage variability.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Docosahexaenoic acid contributes to increased CaMKII protein expression and a tendency to increase nNOS protein expression in differentiated NG108-15 cells. (Pubmed Central) -  Jul 14, 2023   
    NG108-15 cells were seeded in 12-well plates, and after 24 h, the medium was replaced with Dulbecco's modified Eagle's medium containing 1% fetal bovine serum, 0.2 mM dibutyryl cyclic adenosine monophosphate and 100 nM dexamethasone as differentiation-inducing medium...CaMKII protein expression did not change after differentiation without DHA, but was significantly increased on day 6 compared with day 0 with DHA addition. These data indicate that DHA is involved in brain functions by regulating CaMKII and nNOS protein expression.